STAAR SURGICAL CO — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On August 14, 2026, STAAR Surgical granted three stock options to executives: Warren Foust received 131,830 shares (first grant) + 123,659 shares (second grant) = 255,489 total; Deborah Andrews received 29,159 shares. All grants are performance stock options (PSOs) with dual vesting: time-vesting over 36–42 months and performance-vesting tied to three stock price hurdles ($50, $75, $100 per 60-day VWAP). Exercise price set at closing price on grant date. Options expire August 13, 2036. Termination and change-of-control provisions include 90-day tail period for non-cause departures and full acceleration if terminated within 12 months post-acquisition.
Why this rating
Executive equity grants are routine annual compensation. Total shares (284,648) represent ~0.3% of ~95M estimated shares outstanding, immaterial dilution. Stock price hurdles align pay to performance, which is standard governance. No surprise or material business change disclosed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.